Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

College Point, New York Clinical Trials

A listing of College Point, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (16) clinical trials

A Study for the Treatment of Patients With Chronic Hepatitis B

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Phase

2.5 miles

Learn More »

A Study Evaluating ABI-H0731 as Adjunctive Therapy in HBeAg-positive Patients With Chronic Hepatitis B

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients with Chronic Hepatitis B

Phase

2.5 miles

Learn More »

Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach

CHALO builds upon the team's prior research re: cariogenic (R34-DE-022282) and obesogenic behaviors (10, 14, 15). CHALO's intervention components-- home visits, phone support, and "patient navigation" to dental visits-- proved to be feasible and acceptable. In the pilot R34, there were promising behavioral change on all measures. CHALO builds on ...

Phase N/A

4.08 miles

Learn More »

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

PRIMARY OBJECTIVES: I. To evaluate the effects of preoperative neoadjuvant paclitaxel and doxorubicin (doxorubicin hydrochloride)/cyclophosphamide (AC) on: senescence; invasion/motility (tumor microenvironment of metastasis [TMEM] and 67 kDa laminin receptor [67LR]). II. To create a biospecimen repository for future studies derived from patients with breast cancer receiving standard neoadjuvant chemotherapy. OUTLINE: ...

Phase N/A

4.22 miles

Learn More »

Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001

The goal of this study is to explore whether it is possible to add a drug called necitumumab to standard treatment for patients with squamous cell lung cancer that can be surgically removed. This study is important because it will determine whether there is added benefit to giving necitumumab with ...

Phase

4.22 miles

Learn More »

A Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Combination With Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare ...

Phase

4.81 miles

Learn More »

Study to Evaluate Efficacy Safety and Tolerability of MT 7117 in Subjects With Erythropoietic Protoporphyria

This is a Phase II, randomized, double-blind, placebo controlled study to assess the efficacy, tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at Week 22. The total participation ...

Phase

5.23 miles

Learn More »

A Trial of Linaclotide 290 g in Patients With Irritable Bowel Syndrome With Constipation

12 week treatment period followed by 4-week Randomized Withdrawal (RW) Period.

Phase

5.87 miles

Learn More »

GMCI Nivolumab and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

PRIMARY OBJECTIVES: I. To assess the safety/maximum tolerated dose (MTD) of the combination of aglatimagene besadenovec (AdV-tk) given intra-cranially at the time of initial tumor resection followed by valacyclovir (GMCI), nivolumab, and standard of care (radiation therapy [RT]+temozolomide [TMZ]) in patients with high-grade gliomas (HGG). PRIMARY OBJECTIVES: I. To assess ...

Phase

6.07 miles

Learn More »

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

This study will determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors who have progressed on standard of care ...

Phase

6.37 miles

Learn More »